Literature DB >> 19915381

[Successful treatment of T-cell prolymphocytic leukemia (T-PLL) with fludarabine monophosphate].

Akinori Maeda1, Kazuya Iwai, Takafumi Ishibashi.   

Abstract

We report a 79-year-old woman with T-cell prolymphocytic leukemia (T-PLL) who was successfully treated with fludarabine monophosphate. She was admitted to our hospital because of dyspnea on effort. On admission, anemia and hepatosplenomegaly were apparent but lymphadenopathy was absent. Peripheral blood examination showed anemia and leukocytosis with 29.5% abnormal lymphocytes. The bone marrow was infiltrated with 84.1% abnormal lymphocytes. The nucleolus was visible in some of these abnormal cells. These cells were positive for CD2, CD3, CD4, CD5, CD7, CD38, CD52, and negative for CD8, CD10, CD19, CD20, CD25, CD56. Based on these findings, she was diagnosed as having T-PLL. Therapy with oral cyclophosphamide (50 mg/day) was started, but was discontinued because of agranulocytosis. Then, she received intravenous fludarabine monophosphate (30 mg/day) on days 1-5 every four to five weeks. The reticulocyte count increased gradually, and she became free from red cell transfusions. Unfortunately, she finally died from massive gastro intestinal hemorrhage, but T-PLL was well controlled at the time of death.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19915381

Source DB:  PubMed          Journal:  Rinsho Ketsueki        ISSN: 0485-1439


  1 in total

1.  T-cell prolymphocytic leukemia in Japan: is it a variant?

Authors:  Junichi Kameoka; Naoto Takahashi; Hideyoshi Noji; Kazunori Murai; Katsushi Tajima; Yoshihiro Kameoka; Shinji Sato; Tsutomu Shichishima; Yoji Ishida; Hideo Harigae; Kenichi Sawada
Journal:  Int J Hematol       Date:  2012-04-24       Impact factor: 2.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.